Overview
Rare disease company reported Q2 fiscal 2026 net loss of $22.8 mln, up from last year
R&D expenses rose to $14.3 mln due to increased clinical trial activities
Outlook
Rezolute to meet FDA by end of Q1 under Breakthrough Therapy Designation
Topline results for tumor HI study expected in H2 2026
Result Drivers
INCREASED R&D EXPENSES - R&D expenses rose due to increased clinical trial activities and employee-related costs, including severance benefits
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$0.22
Q2 Net Income
-$22.77 mln
Q2 Income From Operations
-$24.22 mln
Q2 Operating Expenses
$24.22 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Rezolute Inc is $5.00, about 48.4% above its February 11 closing price of $3.37
Press Release: ID:nGNXQJyWy
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
